This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (confinement period)
Timeframe: Measured from Day -1 to Day 5.
2-cyanoethyl mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (2-CyEMA) in Urine (confinement period)
Timeframe: Measured from Day -1 to Day 5.
Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (confinement period)
Timeframe: Measured from Day -1 to Day 5.
Total N-nitrosonornicotine (total NNN) in Urine (confinement period)
Timeframe: Measured from Day -1 to Day 5.
Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in Urine (confinement period)
Timeframe: Measured from Day -1 to Day 5.
Carboxyhemoglobin (COHb) in Blood (confinement period)
Timeframe: Measured from Day -1 to Day 5.